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ABSTRACT
Background The rarity of mutations in PALB2, CHEK2 and ATM
make it difficult to estimate precisely associated cancer risks.
Population-based family studies have provided evidence that at least
some of these mutations are associated with breast cancer risk as high
as those associated with rare BRCA2 mutations. We aimed to estimate
the relative risks associated with specific rare variants in PALB2,
CHEK2 and ATM via a multicentre case-control study.
Methods We genotyped 10 rare mutations using the custom iCOGS
array: PALB2 c.1592delT, c.2816T>G and c.3113G>A, CHEK2
c.349A>G, c.538C>T, c.715G>A, c.1036C>T, c.1312G>T, and
c.1343T>G and ATM c.7271T>G. We assessed associations with
breast cancer risk (42 671 cases and 42 164 controls), as well as
prostate (22 301 cases and 22 320 controls) and ovarian (14 542
cases and 23 491 controls) cancer risk, for each variant.
Results For European women, strong evidence of association with
breast cancer risk was observed for PALB2 c.1592delT OR 3.44 (95%
CI 1.39 to 8.52, p=7.1×10−5), PALB2 c.3113G>A OR 4.21 (95% CI
1.84 to 9.60, p=6.9×10−8) and ATM c.7271T>G OR 11.0 (95% CI
1.42 to 85.7, p=0.0012). We also found evidence of association with
breast cancer risk for three variants in CHEK2, c.349A>G OR 2.26
(95% CI 1.29 to 3.95), c.1036C>T OR 5.06 (95% CI 1.09 to 23.5)
and c.538C>T OR 1.33 (95% CI 1.05 to 1.67) (p≤0.017). Evidence
for prostate cancer risk was observed for CHEK2 c.1343T>G OR 3.03
(95% CI 1.53 to 6.03, p=0.0006) for African men and CHEK2
c.1312G>T OR 2.21 (95% CI 1.06 to 4.63, p=0.030) for European
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men. No evidence of association with ovarian cancer was found for
any of these variants.
Conclusions This report adds to accumulating evidence that at least
some variants in these genes are associated with an increased risk of
breast cancer that is clinically important.
INTRODUCTION
The rapid introduction of massive parallel sequencing (MPS)
into clinical genetics services is enabling the screening of mul-
tiple breast cancer susceptibility genes in one assay at reduced
cost for women who are at increased risk of breast (and other)
cancer. These gene panels now typically include the so-called
‘moderate-risk’ breast cancer susceptibility genes, including
PALB2, CHEK2 and ATM.1–3 However, mutations in these
genes are individually extremely rare and limited data are avail-
able with which to accurately estimate the risk of cancer asso-
ciated with them.
Estimation of the age-specific cumulative risk (penetrance) of
breast cancer associated with specific mutations in these three
genes has been limited to those that have been observed more
frequently, such as PALB2 c.1592delT (a Finnish founder muta-
tion), PALB2 c.3113G>A and ATM c.7271T>G. These muta-
tions have been estimated to be associated with a 40% (95% CI
17% to 77%), 91% (95% CI 44% to 100%) and 52% (95% CI
28% to 80%) cumulative risk of breast cancer to the age of
70 years, respectively.4–7 These findings, based on segregation
analyses in families of population-based case series, indicate that
at least some mutations in these ‘moderate-risk’ genes are asso-
ciated with a breast cancer risk comparable to that of the
average pathogenic mutation in BRCA2: 45% (95% CI 31% to
56%).8 However, such estimates are imprecise and, moreover,
may be confounded by modifying genetic variants or other
familial risk factors.
Case-control studies provide an alternative approach to
estimating cancer risks associated with specific variants. This
design can estimate the relative risk directly, without making
assumptions about the modifying effects of other risk factors.
However, because these variants are rare, such studies need to
be extremely large to provide precise estimates.
The clearest evidence for association, and the most precise
breast cancer risk estimates, for rare variants in PALB2, CHEK2
and ATM relate to protein truncating and splice-junction var-
iants.9 10 However, studies based on mutation screening in case-
control studies, combined with stratification of variants by their
evolutionary likelihood suggest that at least some evolutionarily
unlikely missense substitutions are associated with a similar risk
to those conferred by truncating mutations.11–13 For example,
Tavtigian et al12 estimated an OR of 2.85 (95% CI 0.83 to
4.86) for evolutionarily unlikely missense substitutions in the 30
third of ATM, which is comparable to that for truncating var-
iants. Specifically, ATM c.7271C>G has been associated with a
more substantial breast cancer risk in several studies.7 13 Le
Calvez-Kelm et al,11 estimated that the ORs associated with rare
mutations in CHEK2 from similarly designed studies were 6.18
(95% CI 1.76 to 21.8) for rare protein-truncating and splice-
junction variants and 8.75 (95% CI 1.06 to 72.2) for evolution-
arily unlikely missense substitutions.11
It is plausible that monoallelic mutations in PALB2, CHEK2
and ATM could be associated with increased risk of cancers
other than breast cancer, as has been observed for BRCA1 and
BRCA2 and both ovarian and prostate cancers.14–17 However,
with the exception of pancreatic cancer in PALB2 carriers, there
is little evidence to support or refute the existence of such
associations, although a few individually striking pedigrees have
been observed.4 8 18–20
In this study we selected rare genetic variants on the basis
that they had been observed in breast cancer candidate gene
case-control screening projects involving PALB2, CHEK2 or
ATM. These included three rare variants in PALB2: the protein
truncating variants c.1592delT (p.Leu531Cysfs)4 and c.3113
G>A (p.Trp1038*)6 and the missense variant c.2816T>G, (p.
Leu939Trp), six rare missense variants in CHEK2: c.349A>G
(p.Arg117Gly) and c.1036C>T (p.Arg346Cys) predicted to be
deleterious on the basis of evolutionary conservation,11
c.538C>T (p.Arg180Cys), c.715G>A (p.Glu239Lys), c.1312G>T
(p.Asp438Tyr) and c.1343T>G (p.Ile448Ser) and ATM
c.7271T>G (p.Val2424Gly).7 We assessed the association of
these variants with breast, ovarian and prostate risk by case-
control analyses in three large consortia participating in the
Collaborative Oncological Gene-environment Study.21 22
METHODS
Participants
Participants were drawn from studies participating in three con-
sortia as follows:
The Breast Cancer Association Consortium (BCAC), involving
a total of 48 studies: 37 of women from populations with
predominantly European ancestry (42 671 cases and 42 164
controls), 9 of Asian women (5795 cases and 6624 controls)
and 2 of African-American women (1046 cases and 932 con-
trols). All cases had invasive breast cancer. The majority of
studies were population-based or hospital-based case-control
studies, but some studies of European women oversampled cases
with a family history or with bilateral disease (see online
supplementary table S1). Overall, 79% of BCAC cases with
known Estrogen Recptor (ER) status (23% missing) are ER-
positive. The proportion of cases selected by family history that
are ER-positive is 78% (38% missing).
The Prostate Cancer Association Group to Investigate Cancer
Associated Alterations in the Genome (PRACTICAL) involving a
total of 26 studies: 25 included men with European ancestry
(22 301 cases and 22 320 controls) and 3 included African-
American men (623 cases and 569 controls). The majority of
studies were population-based or hospital-based case-control
studies (see online supplementary table S2).
The Ovarian Cancer Association Consortium (OCAC), in-
volving a total of 46 studies. Some studies were case-only and
their data were combined with case-control studies from the
same geographical region (leaving 36 study groupings). Of these
groupings, 33 included women from populations with predomin-
antly European ancestry (16 287 cases (14 542 with invasive
disease) and 23 491 controls), 25 included Asian women (813
cases (720 with invasive disease) and 1574 controls), 17 included
African-American women (186 cases (150 with invasive disease)
and 200 controls) and 29 included women of other ethnic origin
(893 cases (709 with invasive disease) and 864 controls). The
majority of studies were population-based or hospital-based case-
control studies (see online supplementary table S3).
Details regarding sample quality control have been published
previously.22 23 All study participants gave informed consent
and all studies were approved by the corresponding local ethics
committees (see online supplementary tables S1–S3).
Variant selection
We selected for genotyping 13 rare mutations that had been
observed in population-based case-control mutation screening
studies. These variants were PALB2 (c.1592delT, p.
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Leu531Cysfs;4 5 10 c.2323C>T p.Gln775*;20 c.2816T>G, p.
Leu939Trp;2 20 c.3113G>A, p.Trp1038*;2 6 20 c.3116delA, p.
Asn1039IIefs;2 6 20 c.3549C>G, p.Tyr1183*2), CHEK2
(c.349A>G, p.ArgR117Gly; c.538C>T, p.Arg180Cys;
c.715G>A p.Glu239Lys; c.1036C>T, p.Arg346Cys; c.1312G>T,
p.Asp438Tyr; c.1343T>G, p.Ile448Ser)11 and ATM (c.7271T>G,
p.Val2424Gly)7 13 24 see table 1. A DNA sample carrying each of
these variants was included in a plate of control DNAs that was
distributed to each genotyping centre to assist with quality control
and genotype calling.
Genotyping
Three PALB2 variants c.2323C>T (p.Gln775*), c.3116delA
(p.Asn1039IIefs) and c.3549C>G (p.Tyr1183*) were unable to
be designed for measurement on the custom Illumina iSelect
genotyping array and were not considered further (table 1).
Genotyping was conducted using a custom Illumina Infinium
array (iCOGS) in four centres, as part of a multiconsortia collab-
oration as described previously.22 Genotypes were called using
Illumina’s proprietary GenCall algorithm and then, for the data
generated from the rare variant probes, manually confirmed
with reference to the positive control sample. Two per cent of
samples were provided in duplicate by all studies and 270
HapMap2 samples were genotyped in all four genotyping
centres. Subjects with an overall call rate <95% were excluded.
Plates with call rates <90% were excluded on a variant-by-
variant basis. Cluster plots generated for all of the 10 rare var-
iants were manually checked to confirm automated calls (see
online supplementary figure S1).
Statistical methods
The association of each variant with breast, prostate and ovarian
cancer risk was assessed using unconditional logistic regression
to estimate ORs for carriers versus non-carriers, adjusting for
study (categorical). p Values were determined by the likelihood
ratio test comparing models with and without carrier status as a
covariate. We also applied conditional logistic regression, defin-
ing risk sets by study, and found that this made no difference to
the OR estimates, CIs or p values to two significant figures;
since model convergence was a problem for this latter regression
analysis, all subsequent analyses were based on unconditional
logistic regression. For the main analyses of breast cancer risk in
European women, we also included as covariates the first six
principal components, together with a seventh component spe-
cific to one study (Leuven Multidisciplinary Breast Centre
(LMBC)) for which there was substantial inflation not accounted
for by the components derived from the analysis of all studies.
Addition of further principal components did not reduce infla-
tion further. Data from all breast cancer studies were included
to assess statistical significance. Data from cases selected for
inclusion based on personal or family history of breast cancer
were excluded in order to obtain unbiased OR estimates for the
general population of white European women (leaving 37 039
cases and 38 260 controls from 32 studies). Multiple testing was
adjusted for using the Benjamini-Hochberg procedure to control
the false discovery rate, with a significance threshold of 0.05.25
Reported p values are unadjusted unless otherwise stated.
Reported CIs are all nominal. We included two race-specific
principal components in each of the main breast cancer analyses
of Asian and African-American women. Similar analyses were
conducted using the data from PRACTICAL and OCAC, consist-
ent with those used previously.23 26 All analyses were carried
out using Stata: Release V.10 (StataCorp, 2008).
RESULTS
PALB2
In BCAC, PALB2 c.1592delT (Leu531Cysfs) was only observed
in 35 cases and 6 controls, all from four studies from Sweden
and Finland (Helsinki Breast Cancer Study (HEBCS), Kuopio
Breast Cancer Project (KBCP), Oulu Breast Cancer Study
(OBCS) and Karolinska Mammography Project for Risk
Prediction Breast Cancer (pKARMA); see online supplementary
Table 1 Rare genetic variants included in the iCOGS array.
Gene Variant* Amino acid* dbSNP rs
Breast cancer risk estimates
Align-GVGD Reference(s) Designed‡ GenotypedOR (95% CI)
Penetrance†
(95% CI)
PALB2 c.1592delT p.Leu531Cysfs rs180177102 3.94 (1.5-12.1)§ 40% (17–77) na 4, 5, 10 Yes Yes
c.2323C>T p.Gln775* rs180177111 na 25, 26 No No
c.2816T>G p.Leu939Trp rs45478192 C55 20 Yes Yes
c.3113G>A p.Trp1038* rs180177132 95% (44–100) na 2, 6, 20 Yes Yes
c.3116delA p.Asn1039Ilefs rs180177133 na 2 No No
c.3549C>G p.Tyr1183* rs118203998 na 2 No No
CHEK2 c.349A>G p.Arg117Gly rs28909982 8.75 (1.06–72.2)¶ C65 11 Yes Yes
c.538C>T p.Arg180Cys rs77130927 2.47 (0.45–13.49)** C25 11 Yes Yes
c.715G>A p.Glu239Lys rs121908702 1.82 (0.62–5.34)†† C15 11 Yes Yes
c.1036C>T p.Arg346Cys na 8.75 (1.06–72.2)¶ C65 11 Yes Yes
c.1312G>T p.Asp438Tyr na 2.47 (0.45–13.49)** C25 11 Yes Yes
c.1343T>G p.Ile448Ser rs17886163 1.82 (0.62–5.34)†† C15 11 Yes Yes
ATM c.7271T>G p.Val2424Gly rs28904921 52% (28–80) C65 7, 13, 23, 27 Yes Yes
*Human Genome Variation Society (HGVS); reference sequences PALB2, NM_024675.3, NP_078951.2; CHEK2, NM_007194.3, NP_009125.1; ATM, NM_000051.3, NP_000042.3.
†Age-specific cumulative risk of breast cancer to age 70 years.5–7
‡Able to be designed for measurement on the custom Illumina iSelect genotyping array.21 22
§Breast cancer cases unselected for family history of breast cancer.4
¶OR estimated in a combined group of C65 CHEK2 variants.11
**OR estimated in a combined group of C25 CHEK2 variants.11
††OR estimated in a combined group of C15 CHEK2 variants.11
na, not available.
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table S1), giving strong evidence of association with breast
cancer risk (p=7.1×10−5); the OR estimate was 4.52 (95% CI
1.90 to 10.8) based on all studies and 3.44 (95% CI 1.39 to
8.52) based on unselected cases and controls (table 2). We also
found evidence of heterogeneity by ER status (p=0.0023), the
association being stronger for ER-negative disease (OR 6.49
(95% CI 2.17 to 19.4) versus 2.24 (95% CI 1.05 to 7.24) for
ER-positive disease).
PALB2 c.3113G>A (p.Trp1038*) was identified in 44 cases
and 8 controls from nine BCAC studies. Only one carrier of the
variant was of non-European origin. Strong evidence of associ-
ation with breast cancer risk was observed (p=6.9×10−8), with
an estimated OR of 5.93 (95% CI 2.77 to 12.7) based on all
studies and 4.21 (95% CI 1.85 to 9.61) based on unselected
cases and controls. There was no evidence of a differential asso-
ciation by ER status (p=0.15).
Based on unselected cases, the estimated OR associated with
carrying either of these PALB2 variants (c.1592delT or
c.3113G>A) was 3.85 (95% CI 2.09 to 7.09).
PALB2 c.2816T>G (p.Leu939Trp) was identified in 150
cases and 145 controls and there was no evidence of association
with risk of breast cancer. There was no evidence of association
with risk of prostate or ovarian cancer for any of the three
PALB2 variants (see tables 3 and 4).
Table 2 Summary results from Breast Cancer Association Consortium studies of white Europeans (42 671 invasive breast cancer cases and
42 164 controls)
Variant
Frequency*
Controls
Frequency*
Cases OR (95% CI)
LRT
p Value OR† (95% CI)
LRT
p Value†
PALB2§
c.1592delT (p.Leu531Cysfs) 0.00014 0.00082 4.52 (1.90 to 10.8) 7.1×10−5 3.44 (1.39 to 8.52) 0.003
c.2816T>G (p.Leu939Trp) 0.00342 0.00352 1.05 (0.83 to 1.32) 0.70 1.03 (0.80 to 1.32) 0.82
c.3113G>A (p.Trp1038*) 0.00019 0.00101 5.93 (2.77 to 12.7) 6.9×10−8 4.21 (1.84 to 9.60) 1.2×10−4
CHEK2
c.349A>G (p.Arg117Gly) 0.00043 0.00103 2.26 (1.29 to 3.95) 0.003 2.03 (1.10 to 3.73) 0.020
c.538C>T (p.Arg180Cys) 0.00337 0.00370 1.33 (1.05 to 1.67) 0.016 1.34 (1.06 to 1.70) 0.015
c.715G>A (p.Glu239Lys) 0.00021 0.00035 1.70 (0.73 to 3.93) 0.210 1.47 (0.60 to 3.64) 0.40
c.1036C>T (p.Arg346Cys) 0.00005 0.00021 5.06 (1.09 to 23.5) 0.017 3.39 (0.68 to 16.9) 0.11
c.1312G>T (p.Asp438Tyr) 0.00078 0.00082 1.03 (0.62 to 1.71) 0.910 0.87 (0.49 to 1.52) 0.62
c.1343T>G (p.Ile448Ser)‡ 0.00002 0 – – – –
ATM
c.7271T>G (p.Val2424Gly) 0.00002 0.00028 11.6 (1.50 to 89.9) 0.0012 11.0 (1.42 to 85.7) 0.0019
*Proportion of subjects carrying the variant.
†Excluding women from five studies that selected all cases based on family history or bilateral disease and the subset of selected cases from other studies (based on 34 488 unselected
cases and 34 059 controls).
‡CHEK2 c.1343T>G (p.Ile448Ser) was only observed in one control and no cases of white European origin.
§PALB2 c.3113G>A (p.Trp1038*) only observed in the UK, Australia, the USA and Canada. PALB2 c.1592delT (p.Leu531Cysfs) only observed in Finland and Sweden.
LRT, likelihood ratio test; OR, OR for carriers of the variant versus common-allele homozygotes, adjusted for study and seven principal components.
Table 3 Summary results from the Prostate Cancer Association Group to Investigate Cancer Associated Alterations in the Genome studies for
white European men* (22 301 prostate cancer cases and 22 320 controls)
Variant
Frequency†
Controls
Frequency†
Cases OR (95% CI)
LRT
p Value
PALB2
c.1592delT (p.Leu531Cysfs) 0.00018 0.00031 2.06 (0.59 to 7.11) 0.24
c.2816T>G (p.Leu939Trp) 0.00354 0.00381 0.95 (0.69 to 1.29) 0.73
c.3113G>A (p.Trp1038*) 0.00045 0.00027 0.49 (0.18 to 1.36) 0.16
CHEK2‡
c.349A>G (p.Arg117Gly) 0.00063 0.00081 1.46 (0.71 to 3.02) 0.30
c.538C>T (p.Arg180Cys) 0.00341 0.00296 1.02 (0.73 to 1.44) 0.90
c.715G>A (p.Glu239Lys) 0.00018 0.00027 1.47 (0.41 to 5.35) 0.55
c.1036C>T (p.Arg346Cys) 0.00018 0.00022 1.07 (0.28 to 4.07) 0.93
c.1312G>T (p.Asp438Tyr) 0.00049 0.00103 2.21 (1.06 to 4.63) 0.03
c.1343T>G (p.Ile448Ser) 0 0.00009 – –
c.1343T>G (Africans§) 0.019 0.057 3.03 (1.53 to 6.03) 0.001
ATM
c.7271T>G (p.Val2424Gly) 0.00004 0.00027 4.37 (0.52 to 36.4) 0.17
*For white European men, unless otherwise indicated.
†Proportion of subjects carrying the variant.
‡CHEK2 c.1343T>G (p.Ile448Ser) was the only CHEK2 variant observed in African men and was identified in two cases and no controls of white European origin.
§Based on data from 623 and 569 African-American cases and controls, respectively.
LRT, likelihood ratio test; OR, OR for carriers of the variant versus common-allele homozygotes, adjusted for study and seven principal components.
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CHEK2
CHEK2 c.349A>G (p.Arg117Gly) was identified in 44 cases and
18 controls in studies participating in BCAC; all of these women
were of European origin. We found evidence of association with
breast cancer (p=0.003), with little change in the OR after exclud-
ing selected cases (OR 2.03 (95% CI 1.10 to 3.73)).
CHEK2 c.538C>T (p.Arg180Cys) was identified in 158
breast cancer cases and 142 controls in studies of white
Europeans. Evidence of association with breast cancer risk
(p=0.016) was observed, with an unbiased OR estimate of 1.34
(95% CI 1.06 to 1.70). A consistent OR estimate was observed
for Asian women, based on 45 case and 45 control carriers (OR
1.16 (95% CI 0.75 to 1.76)).
CHEK2 c.715G>A (p.Glu239Lys) mutations were identified
in 15 cases and 9 controls, all European women participating in
BCAC and no evidence of association with risk of breast cancer
was observed (p=0.21).
CHEK2 c.1036C>T (p.Arg346Cys) was identified in nine
cases from seven studies and two controls from two different
studies in BCAC (neither control carrier was from a study that had
case carriers), all of European origin. We found evidence of associ-
ation with breast cancer risk (p=0.017) with reduced OR estimate
of 3.39 (95% CI 0.68 to 16.9) after excluding selected cases.
None of the above four CHEK2 variants (CHEK2 c.349A>G
(p.Arg117Gly); c.538C>T (p.Arg180Cys); c.715G>A (p.
Glu239Lys) and c.1036C>T (p.Arg346Cys)) were found to be
associated with an increased risk of prostate or ovarian cancer
(tables 3 and 4). CHEK2 variant c.1312G>T (p.Asp438Tyr)
was not associated with risk of breast cancer for European
women (p=0.91). Variant c.1343T>G (p.Ile448Ser) was not
observed in any breast cancer cases of European or Asian origin.
It was detected in 48 cases and 29 controls of African origin,
giving weak evidence of association (OR 1.52 (95% CI 0.95 to
2.43, p=0.083)). CHEK2 c.1312G>T (p.Asp438Tyr) was identi-
fied in 23 cases and 11 controls from PRACTICAL, all European,
providing evidence of association with prostate cancer risk (OR
2.21 (95% CI 1.06 to 4.63, p=0.030)). CHEK2 c.1343T>G (p.
Ile448Ser) was observed in 35 cases and 11 controls, all African,
participating in PRACTICAL and was also associated with an
increased risk of prostate cancer (OR 3.03 (95% CI 1.53 to 6.03,
p=0.00059)). There was no evidence that these CHEK2 variants
were associated with risk of ovarian cancer (table 4).
ATM
ATM c.7271T>G (p.Val2424Gly) was identified in 12 cases
and 1 control in studies participating in BCAC, all of European
origin, giving evidence of association with breast cancer risk
(p=0.0012). The OR estimate based on unselected studies was
11.0 (95% CI 1.42 to 85.7). There was no evidence of associ-
ation of this variant with prostate or ovarian cancer risk (see
tables 3 and 4).
DISCUSSION
The present report adds to an accumulating body of evidence
that at least some rare variants in so-called ‘moderate-risk’ genes
are associated with an increased risk of breast cancer that is of
clinical relevance.
These findings are presented at a time when detailed informa-
tion about variants in these genes is becoming more readily avail-
able via the translation of diagnostic genetic testing from Sanger
sequencing-based testing platforms to MPS platforms that test
panels of genes in single assays.27–29 The vast majority of infor-
mation about PALB2, CHEK2 and ATM, variants generated from
these new testing platforms is not being used in clinical genetics
services due to lack of reliable estimates of the cancer risk asso-
ciated with individual variants, or groups of variants, in each
gene. Previous analyses have been largely based on selected fam-
ilies, relying on data on the segregation of the variant. The
present study is by far the largest to take a case-control approach.
Consistent with previous reports,5–7 9 11–13 PALB2 c.3113G>A
(p.Trp1038*), PALB2 c.1592delT (p.Leu531Cysfs) and ATM
c.7271T>G (p.Val2424Gly) were found to be associated with
substantially increased risk of breast cancer all with associated
relative risk estimates of 3.44 or greater.
The estimates for the two loss-of-function PALB2 variants
(c.1592delT and c.3113G<A) were consistent with each other
and with estimates based on segregation analysis.5 6 9 We found
no evidence of association with breast cancer for PALB2
c.2816T>G (p.Leu939Trp), with an upper 95% confidence
limit excluding an OR >1.5 which is notable given the
Table 4 Summary results from the Ovarian Cancer Association Consortium studies for white European women (14 542 invasive ovarian cancer
cases and 23 491 controls)
Variant
Frequency*
Controls
Frequency*
Cases OR (95% CI)
LRT
p Value
PALB2
c.1592delT (p.Leu531Cysfs) 0.00004 0.00012 2.50 (0.21 to 29.1) 0.45
c.2816T>G (p.Leu939Trp) 0.00413 0.00399 0.96 (0.69 to 1.34) 0.81
c.3113G>A (p.Trp1038*) 0.00034 0.00031 1.34 (0.36 to 4.97) 0.66
CHEK2
c.349A>G (p.Arg117Gly) 0.00038 0.00031 1.07 (0.32 to 3.60) 0.92
c.538C>T (p.Arg180Cys) 0.00128 0.00160 1.49 (0.83 to 2.67) 0.18
c.715G>A (p.Glu239Lys) 0.00021 0.00037 1.47 (0.42 to 5.22) 0.54
c.1036C>T (p.Arg346Cys)‡ 0 0 – –
c.1312G>T (p.Asp438Tyr) 0.00081 0.00074 0.92 (0.42 to 1.99) 0.83
c.1343T>G (p.Ile448Ser) 0.00009 0 – –
ATM
c.7271T>G (p.Val2424Gly) 0 0.00012 – –
*Proportion of subjects carrying the variant.
‡c.1036C>T (p.Arg346Cys) was not observed in any sample.
LRT, likelihood ratio test; OR, OR for carriers of the variant versus common-allele homozygotes, adjusted for study and seven principal components.
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Align-Grantham Variation Granthan Deviation (Align-GVGD)
score and the observed impact on protein function.30
The estimate for ATM c.7271T>G (p.Val2424Gly) was also
consistent with that found by segregation analysis.7 13 The sub-
stantial increased risk of breast cancer associated with ATM
c.7271T>G (p.Val2424Gly) could be due to the reduction in
kinase activity (with near-normal protein levels) observed for
ATM p.Val2424Gly,31 thus this variant is likely to be acting as a
dominant negative mutation.32
In contrast, we found no evidence of an association with risk
of prostate or ovarian cancer with any of these three variants:
however, the confidence limits were wide; based on the upper
95% confidence limit we could exclude an OR of >1.4 for
prostate cancer for the loss-of-function PALB2 c.3113G>A and
1.9 for c.1592delT and c.3113G>A combined.
We analysed six rare missense variants in CHEK2. Two of
these (CHEK2 c.349A>G (p.Arg117Gly; rs28909982) and
c.1036C>T (p.Arg346Cys)) had evidence of a significant
impact on the protein based on in silico prediction. We pro-
posed these variants for inclusion in the iCOGS design as they
had been identified in 3/1242 cases and 1/1089 controls and
3/1242 cases and 0/1089 controls, respectively, in a population-
based case-control mutation screening study of CHEK2.11 In
that study, Le Calvez-Kelm et al, estimated an OR of 8.75 (95%
CI 1.06 to 72.2) for variants with an Align-GVGD score C65
(based on nine cases and one control). The current analysis pro-
vides confirmatory evidence of this association in a much larger
sample (OR 2.18 (95% CI 1.23 to 3.85)) including 40 unse-
lected case and 18 control carriers. The evidence that CHEK2 is
a breast cancer susceptibility gene is largely based on studies of
protein truncating variants, in particular CHEK2 1100delC.33
Reports of the association of the missense variant I157T, (C15)
and breast cancer risk have been conflicting but a large
meta-analysis involving 15 985 breast cancer cases and 18 609
controls estimated a modest OR of 1.58 (95% CI 1.42 to
1.75).34 We also found evidence (p=0.015) of an association
for c.538C>T (Align-GVGD C25); OR 1.34 (95% CI 1.06 to
1.70), a risk comparable to I157T.
The p values reported above have not been adjusted for mul-
tiple testing. This was not considered appropriate for the asso-
ciations with breast cancer risk of PALB2 c.1592delT,
c.3113G>A and ATM c.7271T>G because these associations
had previously been reported; our aim was to more precisely
estimate the associated relative risks. All three associations with
breast cancer risk reported for CHEK2 variants remained statis-
tically significant after adjusting for the other tests conducted in
relation to breast cancer risk, but not after correcting for all
tests for all cancers. Nevertheless, the findings for CHEK2
c.349A>G and c.1036C>T confirmed those reported previ-
ously, although collectively. The association observed with
CHEK2 c.538C>Trequires independent replication.
Do this approach and new data have an impact on clinical
recommendations for women and families carrying these rare
genetic variants? Although age-specific cumulate risks for cancer
are more informative for genetic counselling and clinical man-
agement of carriers, our study provides information that is rele-
vant to clinical recommendations. As discussed in Easton et al,35
a relative risk of 4 will place a woman in a ‘high-risk’ category (in
the absence of any other risk factor) and a relative risk between 2
and 4 will place a woman in this category if other risk factors are
present. Thus, several of the variants included in this report
(PALB2 c.1592delT; c.3113G>A ATM c.7271T>G) would place
the carrier in a high-risk group, especially if other risk factors,
such as a family history, are present. The high level of breast
cancer risk associated with PALB2 c.1592delT and c.3113G>A
reported here is consistent with the penetrance estimate reported
for a group of loss-of-function mutations in PALB29 and has an
advantage in terms of clinical utility that the estimates in this
study have been made at a mutation-specific level. Therefore, this
work provides important information for risk reduction recom-
mendations (such as prophylactic mastectomy and potentially
salpingo-oophorectomy) for carriers of these variants. However,
further prospective research is required to characterise these risks
and to understand the potential of other risk-reducing strategies
such as salpingo-oophorectomy and chemoprevention.
The consistency of the relative risk estimates with those derived
through family based studies supports the hypothesis that these
variants combine multiplicatively with other genetic loci and
familial risk factors; this information is critical for deriving com-
prehensive risk models. Even with very large sample sizes such as
those studied here, however, it is still only possible to derive indi-
vidual risk estimates for a limited set of variants, and even for
these variants the estimates are still imprecise. This internationally
collaborative approach also has limited capacity to improve risk
estimates for rare variants that are only observed in specific popu-
lations. Inevitably, therefore, risk models will depend on combin-
ing data across multiple variants, using improved in silico
predictions and potentially biochemical/functional evidence to
synthesise these estimates efficiently. It will also be necessary
develop counselling and patient management strategies that can
accommodate a multifactorial approach to variant classification.
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